Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q2 FY21 Earnings Presentation
13 slides from Eris Lifesciences's earnings presentation, Nov 3, 2020
Slide 1: Exchange intimation letter: investor presentation
Date: 03rd November, 2020 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the re
Slide 2: Eris Lifesciences Ltd Q2 FY21 Investor Presentation
ERIS LIFESCIENCES LTD Q2 FY 21 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: Market leading growth in core cardio-metabolic franchise
Q2 FY 21 – MARKET LEADING GROWTH IN CORE CARDIO-METABOLIC FRANCHISE • Continued super-specialty focus and relentless execution leads to 9th consecutive quarter of outperforming covered market in core Cardio metabolic and VMN segment (≈ 80% of sales) • Rank 5th in Oral Diabetes covered market – with
Slide 5: Power brands have leading presence in core therapies
Q2 FY 21 – POWER BRANDS HAVE LEADING PRESENCE IN CORE THERAPIES Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in new generation fast growing molecules Sulfonylurea Glimisave rank 4 in the ≈4,400 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimeper
Slide 6: Power brands have leading presence in core therapies
Q2 FY 21 – POWER BRANDS HAVE LEADING PRESENCE IN CORE THERAPIES High rank in Anti-Hypertensives: the fastest growing and largest segment of Cardiac Care Eritel rank 5 in the ≈3,500 cr Telmisartan and combinations market Eritel CH rank 3 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telm
Slide 7: Consistent long term delivery in core franchise
Q2 FY 21 – CONSISTENT LONG TERM DELIVERY IN CORE FRANCHISE Growth in Cardio Metabolic segment Growth in Cardio Metabolic + VMN (≈ 60% of sales) ( ≈ 80% of sales) 17% 15% 12% 13% 12% 11% 12% 11% 10% 7% 8% 4% FY 18 to FY 20 * Q1 FY21 Q2 FY21 FY 18 to FY 20 * Q1 FY21 Q2 FY21 Eris Covered Market Eris Co
Slide 8: Tailwinds from prescription trends and patent expirations
Q2 FY 21 – TAILWINDS FROM PRESCRIPTION TRENDS AND PATENT EXPIRATIONS Eris’s tailwinds for long-term sustainable growth: • Prescriber preference seen shifting towards established incumbent brands during the last 6 months; this bodes well for Eris with 11 of its Top 15 mother brands being ranked among
Slide 9: Key financial highlights
Q2 FY 21 – KEY FINANCIAL HIGHLIGHTS • Operating Revenue growth of 15.9% yoy • EBITDA growth of 13.6% yoy • Increased in-house manufacturing at Guwahati reduces effective tax liability – Tax as % of PBT = 7.0 % • PAT growth of 16.2% yoy • High Operating Cash Flow generation key pillar of business mod
Slide 10: Standalone income statement
Q2 FY 21 – STANDALONE INCOME STATEMENT Standalone Q2 FY 21 H1 FY 21 INR Millions Q2 FY 21 Q2 FY 20 yoy GR H1 FY 21 H1 FY 20 yoy GR Key highlights of Q2 FY 21 vs Q1 FY 21 (qoq GR) Sale of Products 2,984 2,684 11.2% 5,545 5,282 5.0% Other Operating Income Revenue from Operations 50 3,034 45 2,729 11.5
Slide 11: Consolidated income statement
Q2 FY 21 – CONSOLIDATED INCOME STATEMENT Consolidated Q2 FY 21 Q2 FY 20 Q2 FY 21 H1 FY 21 H1 FY 20 H1 FY21 Break up of INR Millions yoy GR yoy GR Q2 FY 21 Consolidated Sale of Products Q2 FY 21 Q2 FY 20 yoy GR INR Millions Sale of Products 3,253 2,805 16.0% 6,133 5,523 11.0% Other Operating Income 4
Slide 12: Shareholder profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, DIIs 0.73% As on As on As on Name of Shareholder 10.90% 30-Sep-20 30-Jun-20 31-Mar-20 538.2* 457.3* 368.9* Promoters 54.08% 55.55% 55.55% FPI 1 ChrysCapital (Emerald Investment Limited) 5.51% 5.51% 5.51% 11.13%
Slide 13: Thank you
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 12